(Q53907010)

22 May 2018

title

Androgen receptor outwits prostate cancer drugs. (English)

1 reference

22 May 2018

1 reference

2

William B Isaacs

1 reference

22 May 2018

author name string

John T Isaacs

series ordinal

1

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 January 2004

1 reference

22 May 2018

published in

Nature Medicine

1 reference

22 May 2018

volume

10

1 reference

22 May 2018

issue

1

1 reference

22 May 2018

page(s)

26-27

1 reference

22 May 2018

https://scigraph.springernature.com/pub.10.1038/nm0104-26

exact match

0 references

cites work

Molecular determinants of resistance to antiandrogen therapy

1 reference

7 January 2021

Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

1 reference

7 January 2021

Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model

1 reference

7 January 2021

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

1 reference

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

7 January 2021

The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function

1 reference

7 January 2021

Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells

1 reference

7 January 2021

Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function

1 reference

7 January 2021

Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

1 reference

7 January 2021

Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity

1 reference

7 January 2021

Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP.

1 reference

7 January 2021

Identifiers

DOI

10.1038/NM0104-26

1 reference

22 May 2018

Dimensions Publication ID

0 references

1 reference

22 May 2018